Components sourced from donors with at least one previous transfusion in the last two years, and negative for all mandatory microbial investigations (to reduce risk of infection).
Components processed on day 0 (as opposed to those stored at ambient temperature for up to 24hr).
All components should be free of clinically-significant antibodies, including high-titre anti-A and anti-B (to reduce the risk of RBC haemolysis).
Group O (if not group O, then ABO compatible with both maternal and fetal blood group).
Negative for any antigens against which maternal alloantibodies are directed.
In citrate-phosphate-dextrose (CPD) additive solution (reduces the risk of toxicity from mannitol and adenine additives).
Less than 5 days old (to reduce the risk of hyperkalaemia from haemolysed RBCs).
Irradiated (shelf-life 24hrs post-irradiation, to prevent transfusion-associated GVHD).
HbS negative (sickle screen negative).
K-negative (unless the maternal alloantibody is anti-k, in which case k-negative blood should be given)
Haematocrit 0.7-0.85 (to minimise the number of IUT procedures required).
CMV seronegative.
IAT crossmatch-compatible against maternal plasma
Approximate volume 240ml, should not be transfused directly out of 4°C storage because of the risk of fetal bradycardia.
Leave A Comment